



0476 6 JUN 21 19:42

June 19, 2006

Division of Dockets Management
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: **Submission of Data to Supplement the Administrative Record of CTA's Legal Petition on FDA's Regulation of Nanoparticles and Nanomaterial Products**, *FDA Docket No. 2006P-0210/CP 1 and 1878N-0038/CP 17*)

Dear Sir or Madam:

This letter and the enclosed documents supplement the administrative record of the above-referenced legal petition, filed by the International Center for Technology Assessment (CTA) and co-petitioners on 05/16/2006.

The new study is one of the first to examine the potential neurotoxicity of nanoparticles of titanium dioxide, which is widely used in consumer products like sunscreens and cosmetics, and is a central component of CTA's petition. The study indicates that even low concentrations of these manufactured nanoparticles can produce harmful free radicals in brain cells and the potential for brain cell damage.


Long, Thomas C. Navid Saleh, Robert D. Tilton, Gregory V. Lowry, and Bellina Veronesi, *Titanium Dioxide (P25) Produces Reactive Oxygen Species in Immortalized Brain Microglia (BV2): Implications for Nanoparticle Neurotoxicity*, ENVIRON. SCI. TECHNOL. (2006), Web Release Date: 07-Jun-2006, available at, http://pubs3.acs.org/acs/journals/doilookup?in_doi=10.1021/es060589n.

Noreen Parks, *New Nano Headache?*, ScienceNOW Daily News (June 15, 2006).

Study links TiO2 nanoparticles with potential for brain-cell damage, Environ. Sci. & Tech. Online (June 7, 2006).

Copies of the study and news articles on it are enclosed for supplementation of the record before the agency.

Regards,


George A. Kimbrell
Staff Attorney

2006P-0210

SUP 1